Table 1.
Patients’ characteristics (n = 5,562)
| Characteristic | |
|---|---|
| Male, n (%) | 3976 (71.5 %) |
| Age (year), median (IQR) | 39 (35–43) |
| HIV risk factor, n (%) | |
| Intravenous drug use | 3330 (59.9 %) |
| Hemophilia, transfusion, nosocomial | 310 (5.6 %) |
| Heterosexual contact | 990 (17.8 %) |
| Men having sex with men | 731 (13.1 %) |
| Other, unknown | 201 (3.6 %) |
| Known duration of HIV infection (year), median (IQR) | 11 (5–14) |
| CDC stage, n (%) | |
| Stage A | 2731 (49.1 %) |
| Stage B | 1204 (21.6 %) |
| Stage C | 1626 (29.2 %) |
| Under cART at entry, n (%) | 3554 (63.9 %) |
| Under cART during follow up, n (%) | 1648 (29.6 %) |
| cART naive, n (%) | 360 (6.5 %) |
| Deceased | 748 (13.4 %) |
| Known duration of HCV infection (year), median (IQR) | 2 (0–7) |
| HCV risk factor, n (%) | |
| Intravenous drug use | 3588 (64.5 %) |
| Hemophilia, transfusion, nosocomial | 339 (6.1 %) |
| Sexual | 580 (10.4 %) |
| Other, unknown | 1055 (19.0 %) |
| HCV genotype information available | |
| All cohort | 3137 (56.4 %) |
| Patient not spontaneously cured | 3086 (59.4 %) |
| HCV genotype | |
| Genotype 1 | 1676 (53.4 %) |
| Genotype 2 | 99 (3.2 %) |
| Genotype 3 | 763 (24.3 %) |
| Genotype 4 | 584 (18.6 %) |
| Genotype 5 | 4 (0.1 %) |
| Genotype 6 | 4 (0.1 %) |
| Fibrosis evaluation, n (%) | 2869 (51.6 %) |
cART combination antiretroviral therapy, CDC Centers for Disease Control and Prevention, HCV hepatitis C virus, HIV human immunodeficiency virus, IQR interquartile range, SVR sustained virological response